Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies
Investor Relations
Annual Meeting of Shareholders
Latest Financial Results
Q1 2020
Quarterly Results
Ended Mar 31, 2020
Stock Information
Symbol
NYSE American: OGEN
Price
Change
Day Range
52 Wk Range
Company Overview
Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. In addition, Oragenics, Inc. has established an exclusive worldwide channel collaboration with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria.
Contact Information
Investor Relations
CORE IR
John Marco
Managing Director
T: 310-819-2948
johnm@coreir.com
Transfer Agent
Continental Stock Transfer and Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000